{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["Adenocarcinoma","Recurrent Colon Cancer","Adenocarcinoma of the Rectum","Rectal Neoplasms","Stage IV Rectal Cancer","Colorectal Neoplasms","Stage IV Colon Cancer","Recurrent Rectal Cancer","Colonic Neoplasms","Neoplasms","Adenocarcinoma of the Colon"],"disease":["Stage Iv Colon Cancer","Adenocarcinoma","Recurrent Colon Cancer","Rectal Neoplasms","Stage Iv Rectal Cancer","Adenocarcinoma Of The Rectum","Colorectal Neoplasms","Adenocarcinoma Of The Colon","Recurrent Rectal Cancer","Colonic Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2102201"],"location":["United States"],"study_start_month":["2"],"keyword":["Neoplasms by Site","Gastrointestinal Diseases","Gastrointestinal Neoplasms","Rectal Diseases","HSP90 Heat-Shock Proteins","Intestinal Diseases","EGFR protein, human","Digestive System Diseases","Cetuximab","Intestinal Neoplasms","Colonic Diseases","Digestive System Neoplasms"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer","description":"The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.","dates":{"creation":"2011-02-15"},"accession":"2102201","cross_references":{"ClinicalTrials___gov":["NCT01294826"]}}